• ERAD-Engaging Chimeras Enable Rapid Degradation of TM Protei

  2026-07-08

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that selectively degrades transmembrane proteins by hijacking the ER-associated degradation (ERAD) pathway. This advance addresses key challenges in targeted protein degradation, offering high selectivity and efficacy with implications for cancer and membrane protein research.

• Sex Differences in Cannabinoid Withdrawal: Insights from WIN

  2026-07-08

  This study systematically characterizes somatic and anxiety-like behaviors during withdrawal from the synthetic cannabinoid agonist WIN 55,212-2 in male and female rats. The findings reveal qualitative sex differences in withdrawal behaviors, informing both endocannabinoid system research and the translational modeling of cannabinoid dependence.

• GPR35-KLF5 Circuitry Decodes Mucosal Damage for Epithelial R

  2026-07-07

  This study reveals a metabolic sensing mechanism in which GPR35 detects tryptophan metabolite signals in response to colonic injury, activating a KLF5-driven repair program via the PI3K-AKT-mTOR pathway. The findings clarify how intestinal epithelial cells orchestrate proliferation and migration after mucosal damage, providing new insights for ulcerative colitis research.

• Angiotensin (1-7): Applied Protocols and Research Innovation

  2026-07-07

  Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) is revolutionizing experimental workflows in anti-fibrotic, metabolic, and neuroprotective research by precisely modulating PI3K/AKT and ERK pathways. With validated protocols, high solubility, and peer-reviewed insights, APExBIO's reagent empowers translational scientists to bridge bench findings and clinical potential.

• Universal nPEC Method for Dual-Loaded Liposome Efficiency An

  2026-07-06

  This study introduces and validates a nanoparticle exclusion HPLC (nPEC) method as an accurate, robust, and universally applicable approach for determining encapsulation efficiency in dual-loaded liposomes, addressing the challenges posed by drugs with differing physicochemical properties. The findings provide a significant advance for researchers optimizing liposomal co-delivery systems, combination therapy protocols, and nanomedicine development.

• Pentoxifylline (SKU C3816): Reliable Solutions for Inflammat

  2026-07-06

  This article addresses real-world laboratory challenges in cell-based inflammation and immunomodulation assays, highlighting how Pentoxifylline (SKU C3816) from APExBIO offers reproducible, data-driven outcomes. We present scenario-driven Q&A blocks—grounded in literature and product evidence—to guide protocol optimization, data interpretation, and vendor selection for researchers working with this versatile phosphodiesterase inhibitor.

• KR-12 (human) TFA: Mechanisms, Benchmarks & Protocol Integra

  2026-07-05

  KR-12 human antimicrobial peptide is the smallest active fragment of LL-37 with a narrow, defined antimicrobial spectrum and unique copper-binding properties. Its activity is highly sequence-dependent, non-toxic to mammalian cells at working concentrations, and validated for anti-biofilm, LPS-neutralizing, and immunomodulatory research applications.

• Enhanced Antifungal Activity via 13-Benzyl Berberrubine Deri

  2026-07-04

  The reference study reports the synthesis of novel 13-(substituted benzyl) berberine and berberrubine derivatives with improved antifungal activity against clinically relevant fungi. This structure-activity relationship work advances the design of isoquinoline alkaloids, informing future research into multi-target antifungal agents.

• Ibuprofen Toxicology and Biodegradation: Environmental Impli

  2026-07-03

  This review addresses the environmental challenges posed by widespread ibuprofen use, highlighting its persistence as a contaminant and the limited effectiveness of current removal strategies. The paper emphasizes the urgent need for improved biodegradation approaches and underscores the compound's biochemical properties that complicate environmental remediation.

• Forskolin: Advancing cAMP Signaling from Mechanism to Medici

  2026-07-03

  This thought-leadership article explores how Forskolin, a direct adenylate cyclase activator, drives innovation in translational research. Blending mechanistic insights with hands-on protocol guidance and cross-domain relevance, we link foundational cAMP biology to state-of-the-art human neuron models, regenerative medicine, and disease modeling—including new evidence on HSV-1 reactivation. We compare APExBIO’s Forskolin to conventional tools, propose strategic best practices, and offer a mature, forward-looking perspective for translational scientists.

• Gamma-linolenic Acid (GLA): Translational Insights for Infla

  2026-07-02

  Explore the multifaceted roles of Gamma-linolenic acid (GLA) in anti-inflammatory research and immune modulation. This article delivers a deep scientific perspective, practical assay strategies, and unique insights into GLA’s translational impact on inflammation and humoral immunity.

• Tanshinone IIA Inhibits Key Psoriasis Pathways: Mechanistic

  2026-07-02

  This study demonstrates that Tanshinone IIA, a component of Xiao-Yin decoction, alleviates psoriasis by suppressing IL-17/IL-23 and PTGS2/NF-κB/AP-1 signaling in keratinocytes and mouse models. The findings establish mechanistic evidence for the anti-inflammatory and anti-proliferative effects of Tanshinone IIA, with implications for optimizing combinatorial and targeted therapeutic strategies in inflammatory skin disease.

• CHI3L1-IN-5 (Compound Z17): Advanced Neuroinflammation Workf

  2026-07-01

  CHI3L1-IN-5 (Compound Z17) delivers precise CHI3L1 inhibition and robust CNS penetration for advanced neurodegeneration models. This article translates structure-activity breakthroughs and peer-reviewed protocols into actionable workflow strategies, troubleshooting, and assay optimization for Alzheimer's and neuroinflammation research.

• Dimethyloxalylglycine (DMOG): Technical Use & Protocol Guida

  2026-07-01

  Dimethyloxalylglycine (DMOG) enables precise simulation of hypoxic and inflammatory conditions in preclinical research by stabilizing hypoxia-inducible factor (HIF) proteins. It is not suitable for diagnostic or therapeutic applications, and optimal results require careful attention to solubility, dosing, and workflow controls.

• Deracoxib: Selective COX-2 Inhibitor for Inflammation Resear

  2026-06-30

  Deracoxib is a selective COX-2 inhibitor with defined anti-inflammatory, analgesic, and antitumor effects in veterinary research. It demonstrates cell-type specific cytotoxicity and synergy with doxorubicin, enabling precise modeling of pain and inflammation. Robust evidence supports its integration into inflammation assays and cancer biology workflows.

15505 records 1/1034 page Next 12345 下5页 Last page